SCHEMBL7674963

SCHEMBL7674963

CCc1cc(C(=O)c2c(Cc3ccccc3)sc(C)c2C)ccc1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.45
ALDH1A1 P00352 5/20 0.45
LMNA P02545 3/20 0.45
GAA P10253 2/20 0.45
MEN1 O00255 1/20 0.45
POLB P06746 1/20 0.45
KMT2A Q03164 1/20 0.45
ACHE P22303 6/20 0.42
BCHE P06276 4/20 0.42
HPGD P15428 5/20 0.42
USP2 O75604 1/20 0.42
ALOX15 P16050 1/20 0.42
RECQL P46063 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
HSD17B10 Q99714 1/20 0.42
KDM4E B2RXH2 3/20 0.41
CYP1A2 P05177 2/20 0.40
CYP2D6 P10635 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7671504 0.93 MAPT (0.42) MAPTALDH1A1LMNAGAAMEN1
SCHEMBL7672920 0.87 ACHE (0.55) MAPTALDH1A1LMNAGAAMEN1
SCHEMBL7670851 0.86 ALDH1A1 (0.46) MAPTALDH1A1LMNAGAAMEN1
SCHEMBL7676828 0.85 PTGS1 (0.47) MAPTALDH1A1LMNAGAAMEN1
SCHEMBL7676256 0.84 PTGS1 (0.45) MAPTALDH1A1LMNAGAAMEN1
SCHEMBL6735126 0.81 MAPT (0.40) MAPTALDH1A1LMNAGAAMEN1
SCHEMBL6705187 0.81 MAPT (0.50) MAPTALDH1A1LMNAGAAMEN1
SCHEMBL7668333 0.79 MAPT (0.48) MAPTALDH1A1LMNAGAAMEN1
SCHEMBL7669639 0.78 ACHE (0.42) MAPTALDH1A1ACHEBCHEHPGD
SCHEMBL7670157 0.76 ALDH1A1 (0.47) MAPTALDH1A1LMNAGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6444670-B2 ENZYME INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES; ANTI-DIABETIC AGENTS; TREATMENT OF INSULIN RESISTANCE ASSOCIATED WITH OBESITY, GLUCOSE INTOLERANCE, DIABETES MELLITUS, HYPERTENSION AND ISCHEMIC DISEASES OF VESSELS WYETH 2002-09-03 US disclosed
US-20020002187-A1 Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin-resistance and hyperglycemia WYETH 2002-01-03 US disclosed
US-6251936-B1 ADMINISTERING TO THE PATIENT SUFFERING FROM METABOLIC DISORDERS MEDIATED BY INSULIN RESISTANCE OR HYPERGLYCEMIA A BENZENE OR PYRIDINE SUBSTITUTED INDOLE OR BENZOTHIOPHENE DERIVATIVES OR SALTS AMERICAN HOME PRODUCTS CORPORATION 2001-06-26 US disclosed
EP-1077969-A1 BENZOTHIOPHENES, BENZOFURANS, AND INDOLES USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 2001-02-28 EP disclosed
WO-1999061435-A1 BENZOTHIOPHENES, BENZOFURANS, AND INDOLES USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 1999-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020002187-A1 Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin-resistance and hyperglycemia IRS1, INSR, GPR119 MAPT 4113/4885ALDH1A1 1497/4885LMNA 3357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.